Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
10,154
archived clinical trials in
Other Indications

Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
CCOP - Northern Indiana CR Consortium
mi
from
South Bend, IN
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
CCOP - Northern Indiana CR Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Michiana Hematology Oncology PC - La Porte
mi
from
Westville, IN
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Michiana Hematology Oncology PC - La Porte
mi
from
Westville, IN
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Cancer Center of Kansas, PA - Medical Arts Tower
mi
from
Wichita, KA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Cancer Center of Kansas, PA - Medical Arts Tower
mi
from
Wichita, KA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Cancer Center of Kansas, PA - Wichita
mi
from
Wichita, KA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Cancer Center of Kansas, PA - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
CCOP - Wichita
mi
from
Wichita, KA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
York Hospital's Oncology Treatment Center
mi
from
York, ME
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
York Hospital's Oncology Treatment Center
mi
from
York, ME
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Green Bay Oncology, Limited - Escanaba
mi
from
Escanaba, MI
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Green Bay Oncology, Limited - Escanaba
mi
from
Escanaba, MI
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Butterworth Hospital at Spectrum Health
mi
from
Grand Rapids, MI
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Butterworth Hospital at Spectrum Health
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
William Beaumont Hospital - Royal Oak Campus
mi
from
Royal Oak, MI
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
William Beaumont Hospital - Royal Oak Campus
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
Saint Joseph, MI
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Duluth Clinic Cancer Center - Duluth
mi
from
Duluth, MN
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Duluth Clinic Cancer Center - Duluth
mi
from
Duluth, MN
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
CCOP - Metro-Minnesota
mi
from
Saint Louis Park, MN
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
CCOP - Metro-Minnesota
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Mission Hospitals - Memorial Campus
mi
from
Asheville, NC
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Mission Hospitals - Memorial Campus
mi
from
Asheville, NC
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
AnMed Cancer Center
mi
from
Anderson, SC
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
AnMed Cancer Center
mi
from
Anderson, SC
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
CCOP - Northwest
mi
from
Tacoma, WA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
CCOP - Northwest
mi
from
Tacoma, WA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Marshfield Clinic Cancer Care at Regional Cancer Center
mi
from
Eau Claire, WI
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Marshfield Clinic Cancer Care at Regional Cancer Center
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Marshfield Clinic - Lakeland Center
mi
from
Minocqua, WI
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Marshfield Clinic - Lakeland Center
mi
from
Minocqua, WI
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Cancer Centre of Southeastern Ontario at Kingston General Hospital
mi
from
Kingston,
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Cancer Centre of Southeastern Ontario at Kingston General Hospital
mi
from
Kingston,
Click here to add this to my saved trials
BEST (Burn Center Evaluation of Standard Therapies) Ventilator Mode Study-
BEST (Burn Center Evaluation of Standard Therapies) Ventilator Mode Study: A Prospective Randomized Controlled Trial
Status: Enrolling
Updated:  9/8/2015
United States Army Institute of Surgical Research
mi
from
Fort Sam Houston, TX
BEST (Burn Center Evaluation of Standard Therapies) Ventilator Mode Study-
BEST (Burn Center Evaluation of Standard Therapies) Ventilator Mode Study: A Prospective Randomized Controlled Trial
Status: Enrolling
Updated: 9/8/2015
United States Army Institute of Surgical Research
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Sudden Sensorineural Hearing Loss
A Phase I & II Open-label Study of the Effects of Anakinra (Kineret) in Corticosteroid-resistant Subjects With Sudden Sensorineural Heaing Loss (SSNHL)
Status: Enrolling
Updated:  9/8/2015
North Shore-LIJ Hearing and Speech Center
mi
from
New Hyde Park, NY
Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Sudden Sensorineural Hearing Loss
A Phase I & II Open-label Study of the Effects of Anakinra (Kineret) in Corticosteroid-resistant Subjects With Sudden Sensorineural Heaing Loss (SSNHL)
Status: Enrolling
Updated: 9/8/2015
North Shore-LIJ Hearing and Speech Center
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Oral Alkali Production and Caries Prevention in Children (Cross-sectional Component)
Oral Alkali Production and Caries Prevention in Children (Cross-sectional Component)
Status: Enrolling
Updated:  9/14/2015
Dental Clinical Research Unit, University of Florida
mi
from
Gainesville, FL
Oral Alkali Production and Caries Prevention in Children (Cross-sectional Component)
Oral Alkali Production and Caries Prevention in Children (Cross-sectional Component)
Status: Enrolling
Updated: 9/14/2015
Dental Clinical Research Unit, University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Aurora Presbyterian Hospital
mi
from
Aurora, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Aurora Presbyterian Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Boulder Community Hospital
mi
from
Boulder, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Boulder Community Hospital
mi
from
Boulder, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Penrose Cancer Center at Penrose Hospital
mi
from
Colorado Springs, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Penrose Cancer Center at Penrose Hospital
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
St. Anthony Central Hospital
mi
from
Denver, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
St. Anthony Central Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Porter Adventist Hospital
mi
from
Denver, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Presbyterian - St. Luke's Medical Center
mi
from
Denver, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Presbyterian - St. Luke's Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
St. Joseph Hospital
mi
from
Denver, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
St. Joseph Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Rose Medical Center
mi
from
Denver, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Rose Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
CCOP - Colorado Cancer Research Program, Inc.
mi
from
Denver, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
CCOP - Colorado Cancer Research Program, Inc.
mi
from
Denver, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Swedish Medical Center
mi
from
Englewood, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Swedish Medical Center
mi
from
Englewood, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
mi
from
Grand Junction, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
mi
from
Grand Junction, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
North Colorado Medical Center
mi
from
Greeley, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
North Colorado Medical Center
mi
from
Greeley, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Hope Cancer Care Center at Longmont United Hospital
mi
from
Longmont, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Hope Cancer Care Center at Longmont United Hospital
mi
from
Longmont, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
McKee Medical Center
mi
from
Loveland, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
McKee Medical Center
mi
from
Loveland, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
St. Mary - Corwin Regional Medical Center
mi
from
Pueblo, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
St. Mary - Corwin Regional Medical Center
mi
from
Pueblo, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
North Suburban Medical Center
mi
from
Thornton, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
North Suburban Medical Center
mi
from
Thornton, CO
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Exempla Lutheran Medical Center
mi
from
Wheat Ridge, CO
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Exempla Lutheran Medical Center
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials